The fourth case is related to nephrotic syndrome due to MCD 15 days post initiation of a combination therapy of vascular endothelial growth factor receptor inhibitor (anti-VEGF) and immune checkpoint inhibitor (ICPI) for a patient suffering from metastatic renal cell carcinoma. The gene discussed is VEGFA; the disease is nephrotic syndrome.